SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: September 16, 2013
(Date of earliest event reported)
WhiteHorse Finance, Inc.
(Exact name of registrant as specified in
(State or other jurisdiction
1450 Brickell Avenue, 31st
|(Address of principal executive offices)
(Registrant’s telephone number, including
(Former Name or Former Address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On September 16, 2013, Acella Pharmaceuticals, LLC (“Acella”)
repaid in full WhiteHorse Finance, Inc.’s (the “Company”) investment in the first lien secured term loan to Acella
due December 30, 2015. In connection with the repayment by Acella, the Company received approximately $59.7 million in principal
prepayment. The Company also received a 3% pre-payment fee.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: September 18, 2013
||WHITEHORSE FINANCE, INC.
/s/ Alastair G. C. Merrick
Alastair G. C. Merrick
||Chief Financial Officer & Treasurer